The HDAC8 Knockout MCF-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the MCF-7 human breast adenocarcinoma line. This heterogeneous pool carries diverse loss-of-function mutations in HDAC8, providing a robust model for studying gene function without clonal bias. The polyclonal format ensures target-gene disruption across the population, making it suitable for investigating HDAC8 in a breast cancer context. These cells are ready for immediate use in epigenetic and drug discovery research.
MCF-7 is an epithelial cell line isolated from the pleural effusion of a metastatic breast adenocarcinoma patient. It expresses estrogen receptor alpha, serving as a key model for estrogen receptor-positive breast cancer. The cells retain hormone responsiveness and relevant signaling pathways, enabling studies of estrogen-driven proliferation, apoptosis, and epigenetic regulation. This background offers a physiologically relevant platform to examine the intersection of histone deacetylation and estrogen receptor biology.
HDAC8 is a class I histone deacetylase that deacetylates histones H3 and H4 and non-histone substrates SMC3, p53, and HSP90, promoting chromatin condensation and transcriptional repression. It regulates cell cycle progression, DNA repair, and apoptosis, and is controlled by the transcription factor MYC and inhibited by vorinostat and trichostatin A. Through interactions with SMC3, p53, and HSP90, HDAC8 links epigenetic modifications to cohesin dynamics, tumor suppressor stability, and protein homeostasis.
In MCF-7 cells, HDAC8 knockout disrupts histone acetylation homeostasis, impairing estrogen receptor signaling, cell cycle progression, and DNA repair. This model is valuable for dissecting HDAC8??s role in breast cancer pathogenesis and for exploring cohesin acetylation defects relevant to Cornelia de Lange syndrome. The polyclonal nature allows assessment of heterogeneous mutation outcomes, providing insight into loss-of-function phenotypes in a hormone-sensitive background.
These polyclonal knockout cells support diverse applications, including HDAC inhibitor target validation, cohesin acetylation studies, and functional genomics of histone deacetylases. Compatible assays include western blot for histone acetylation, RT-qPCR for gene expression, ChIP-qPCR for histone marks, and functional assays for proliferation, apoptosis, drug sensitivity, and migration/invasion. This tool enables comprehensive investigation of HDAC8 in breast cancer and preclinical drug testing. For further information, contact Ascent Research.
